FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
6 March 2026
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 4 March 2026,
certain Persons Discharging Managerial Responsibilities of the
Company (PDMRs) were granted awards of the Company's ordinary
shares of $0.25 each (Ordinary Shares) under the terms of the
AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca
Performance Share Plan (AZPSP), as detailed in the table
below.
|
PDMR
|
Position
|
Ordinary Shares granted under the AZDBP
|
Ordinary Shares granted under the AZPSP
|
Award price per Ordinary Share
|
|
Pascal Soriot
|
Executive Director and Chief Executive Officer
|
13,970
|
89,611
|
£152.42
|
|
Aradhana Sarin
|
Executive Director and Chief Financial Officer
|
5,258
|
37,135
|
£152.42
|
The AZDBP award represents the portion of each PDMR's annual bonus
for 2025 that they are required to defer into shares. The Ordinary
Shares granted under the AZDBP are subject to a three-year holding
period and are due to vest on the third anniversary of
grant.
The AZPSP award is subject to a combination of performance measures
focused on scientific, commercial, financial and sustainability
performance. The performance measures will be assessed over a
three-year performance period (1 January 2026 to 31 December 2028).
The Ordinary Shares granted under the AZPSP are subject to a
two-year holding period following the performance period, and are
due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2025, which is
available on the Company's website at www.astrazeneca.com/annualreport2025
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Deferred Bonus Plan
and the AstraZeneca Performance Share Plan.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£152.42
|
103,581
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
4 March 2026
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Grants of share awards under the AstraZeneca Deferred Bonus Plan
and the AstraZeneca Performance Share Plan.
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
£152.42
|
42,393
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
4 March 2026
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 06 March 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|
